Upper-extremity synovial sarcoma required more staged surgery, while lower-extremity disease carried more complications and metastases.
Commentary|Videos|July 25, 2025
Considerations for Molecular Testing in Dermatology Practice: Virginia Sybert, MD
Fact checked by: Christina Mattina
Listen
0:00 / 0:00
Virginia Sybert, MD, clinical professor of medical genetics at the University of Washington, discussed what dermatologists should know about molecular testing in clinical practice.
Advertisement
Virginia Sybert, MD, clinical professor of medical genetics at the University of Washington, discussed what dermatologists should know about molecular testing in clinical practice. She discussed the importance of collaboration between dermatologists and geneticists at the
Transcript
How should dermatologists approach molecular testing in clinical practice?
My charge was to talk about the use of molecular testing, or DNA testing, in a dermatology clinic. And what people should take away is that, number 1, you want to make sure that you're doing testing that's necessary. Number 2, that you're doing the right kind of testing, and number 3, that you know how to interpret those results. And I think that all of those things are difficult and that it is appropriate to engage help. So I really encourage the interaction of geneticists and dermatologists to deal with all of these things; that's the takeaway.
What gaps exist in treatment availability for dermatologic conditions?
I think that there are gaps in treatment for everything in medicine, and we really have the insurance companies to blame—single payer, please. We have difficulty with getting medications and getting treatment paid for; we have difficulty getting access to treatment and finding a pharmacy in your area. I mean, there isn't any aspect of medical care that's not being hampered by economic forces.
Advertisement
Related to this article
In the US alone, 1.1 million individuals are living with the progressive neurodegenerative movement disorder, and 90,000 are diagnosed each year.
Baricitinib is now FDA approved for adolescents 12 and older with severe alopecia areata, extending the once-daily pill beyond adults.
A new type of eye drug matched standard anti-VEGF therapy in a large trial for diabetic macular edema, a disease affecting 1.6 million Americans.
At a Stakeholder Interchange convened by The American Journal of Managed Care® in Tampa, Florida, an academic-community mix of hematologist-oncologists and pharmacists debated prior authorization, site-of-care payment disparities, and how aggressively to push bispecific antibody regimens to community practices treating patients with relapsed/refractory multiple myeloma.
Portuguese patch testing finds many chronic hand eczema cases link to allergic contact dermatitis—especially occupational exposures like methylisothiazolinone, HEMA acrylates, thiuram mix, nickel.
The National Comprehensive Cancer Network update on mantle cell lymphoma puts covalent BTK inhibitors, MRD testing, and TP53 sequencing at the center of frontline care, while adding pirtobrutinib and a pair of CAR T-cell therapies for disease that progresses on a BTK inhibitor.
CDC's David A. Siegel, MD, MPH, on rising cancer diagnoses, falling deaths, and where CDC's cancer control resources go next.
Advertisement
Advertisement
Trending on AJMC
1
Peptide Regulation Debate Intensifies After FDA Advisory Panel's Controversial Vote
2
Health System Pharmacies Keep Patients on GLP-1 Therapy
3
Tavapadon for Parkinson Disease Approved by FDA
4
NCCN Journal Publishes Guidelines Update in Mantle Cell Lymphoma
5